Skip to content

Comparision of short-term outcomes between Robotic and laparoscopic distal gastrectomy for local advanced gastric cancer: a multi-insititutional prospective randomized clinical trial

Comparision of short-term outcomes between Robotic and laparoscopic-assisted distal gastrectomy for local advanced gastric cancer: a multi-insititutional prospective randomized clinical trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000032670
Enrollment
Unknown
Registered
2020-05-06
Start date
2020-05-01
Completion date
Unknown
Last updated
2020-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

laparoscopy group:laparoscopic-assisted distal gastrectomy
robotic group:robotic-assisted distal gastrectomy

Sponsors

The First Medical Centre of PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Pathologically diagnosed patients with advanced gastric adenocarcinoma; 2. Age: 18 years <= age <= 80 years; 3. According to AJCC/UICC version 8: cTNM stage: cT2-4aN0-3M0; 4. Without surgical contraindications; 5. ASA score III or less; 6. Signed informed consent; 7. The eastern cooperative tumor group (ECOG) score: 0-1; 8. Preoperative evaluation showed that the tumor was located in the middle and lower 1/3 of the stomach.

Exclusion criteria

Exclusion criteria: 1. Serious mental disorder; 2. Women with pregnant and suckling period; 3. Previous history of upper abdominal surgery (except laparoscopic cholecystectomy); 4. Gastric resection, endoscopic mucosal resection or endoscopic submucosal dissection, gastric stump cancer; 5. History of unstable angina pectoris or myocardial infarction within the previous 6 months; 6. Preoperative chemoradiotherapy; 7. History of other malignant tumors within the past 5 years (except thyroid papillary carcinoma); 8. Metastatic lymph nodes around the stomach >= 3cm; 9. Patients requiring other operations; 10. Severe respiratory disease (FEV1 < 50%); 11. Study within a month before the ongoing systemic steroid treatment.

Design outcomes

Primary

MeasureTime frame
30-day postoperative morbidity;

Secondary

MeasureTime frame
quality of life;

Countries

China

Contacts

Public ContactBo Wei

Department of General Surgery, the First Medical Centre of PLA General Hospital

weibo@vip.163.com+86 13910038055

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026